Optimised glucocorticoid therapy: The sharpening of an old spear

Lancet

Volumn 365, Issue 9461, 2005, Pages 801-803

  Buttgereit, Frank ^a   Burmester, Gerd Rüdiger ^a   Lipworth, Brian J ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; ANTIINFLAMMATORY AGENT; BECLOMETASONE; BETAMETHASONE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CORTISONE; DEXAMETHASONE; FLUORINATED STEROID; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ANTAGONIST; GLYCYRRHETINIC ACID; METHYLPREDNISOLONE; NITROSO DERIVATIVE; PREDNISONE; SEGRA; STEROID; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ARTHRITIS; BODY MASS; BONE MINERAL; CORTICOSTEROID THERAPY; CROHN DISEASE; CUSHINGOID SYNDROME; DIABETES MELLITUS; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; ECZEMA; GLAUCOMA; GROWTH RETARDATION; HUMAN; NEPHROTIC SYNDROME; NONHUMAN; NOSE INFECTION; OBESITY; OSTEOPOROSIS; PHOBIA; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN ATROPHY; SPINE; WEIGHT GAIN;

EID: 14644429018     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)71005-9     Document Type: Review

References (21)

1. Schacke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharm Ther. 96:2002;23-43
2. Buttgereit F, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 50:2004;3408-3417
3. Kirwan JR, Bálint G, Szebenyi B. Anniversary: 50 years of glucocorticoid treatment in rheumatoid arthritis. Rheumatology. 38:1999;100-102
4. Buttgereit F, da Silva JA, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 61:2002;718-722
5. Leonard MB, Feldman HI, Shults J, Zemel BS, Foster BJ, Stallings VA. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med. 351:2004;868-875
6. Bachrach LK. Bare-bone fact - children are not small adults. N Engl J Med. 351:2004;924-926
7. Laverman P, Boerman OC, Oyen WJ, Dams ET, Storm G, Corstens FH. Liposomes for scintigraphic detection of infection and inflammation. Adv Drug Deliv Rev. 37:1999;225-235
8. Dams ET, Oyen WJ, Boerman OC, et al. 99mTc-PEG liposomes for the detection of infection and inflammation: clinical evaluation. J Nucl Med. 41:2000;622-630
9. Metselaar JM, Wauben MH, Wagenaar-Hilbers JP, Boerman OC, Storm G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum. 48:2003;2059-2066
10. Schmidt J, Metselaar JM, Wauben MH, Toyka KV, Storm G, Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain. 126:2003;1895-1904
11. Perretti M, Paul-Clark MJ, Mancini L, Flower RJ. Generation of innovative anti-inflammatory and anti-arthritic glucocorticoid derivatives that release NO: the nitro-steroids. Dig Liver Dis. 35:(suppl 2):2003;41-48
12. Connelly L, Palacios-Callender M, Ameixa C, Moncada S, Hobbs AJ. Biphasic regulation of NF-κB activity underlies the pro- and anti-inflammatory actions of nitric oxide. J Immunol. 166:2001;3873-3881
13. Paul-Clark M, Del Soldato P, Fiorucci S, Flower RJ, Perretti M. 21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties. Br J Pharmacol. 131:2000;1345-1354
14. Paul-Clark MJ, Mancini L, Del Soldato P, Flower RJ, Perretti M. Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc Natl Acad Sci USA. 99:2002;1677-1682
15. Paul-Clark MJ, Roviezzo F, Flower RJ, et al. Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J Immunol. 171:2003;3245-3252
16. O'Brien RM, Noisin EL, Suwanichkul A, et al. Hepatic nuclear factor 3- and hormone-regulated expression of the phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein 1 genes. Mol Cell Biol. 15:1995;1747-1758
17. Yoshiuchi I, Shingu R, Nakajima H, et al. Mutation/polymorphism scanning of glucose-6-phosphatase gene promoter in noninsulin-dependent diabetes mellitus patients. J Clin Endocrinol Metab. 83:1998;1016-1019
18. Schacke H, Schottelius A, Döcke W, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA. 101:2004;227-232
19. Lin CW, Nakane M, Stashko M, et al. Trans-activation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcyclohexen-3-y1)-1 h-[1]benzopyrano[3,4-f]quinoline (A276575) and its four stereoisomers. Mol Pharmacol. 62:2002;297-303
20. Miner JN. Designer glucocorticoids. Biochem Pharmacol. 64:2002;355-361
21. Coghlan MJ, Jacobson PB, Lane B, et al. A novel anti-inflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol. 17:2003;860-869